Patents by Inventor Michael Kuziora

Michael Kuziora has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TUMOR MUTATIONAL BURDEN ASSOCIATED WITH SENSITIVITY TO IMMUNOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
    Publication number: 20230193399
    Abstract: The disclosure generally relates to methods for treating urothelial carcinoma patients based on use of PD-L1 expression, blood-based tumor mutation burden, and identification of mutations in circulating tumor DNA associated with sensitivity or resistance to immunotherapy to predict overall survival in patients treated with durvalumab.
    Type: Application
    Filed: May 21, 2021
    Publication date: June 22, 2023
    Inventors: Han SI, Michael KUZIORA, Brandon W. HIGGS
  • TUMOR BURDEN AS MEASURED BY CELL FREE DNA
    Publication number: 20180282417
    Abstract: Disclosed are methods for treating cancer (e.g., solid tumor cancers, lung cancer, bladder head and neck cancer) with an anti-PD-L1 antibody in a patient identified as being responsive to anti-PD-L1 antibody therapy by detecting a mutation in one or more disclosed circulating tumor DNA (ctDNA) markers. Also disclosed are methods for determining the efficacy of anti-PD-L1 therapeutic antibody treatment in a patient having lung cancer or bladder cancer comprising detecting variant allele frequency in ctDNA in plasma samples and determining the difference of the variant allele frequency in ctDNA between the first and at least second plasma samples, wherein a decrease in the variant allele frequency in the at least second plasma sample relative to the first plasma sample identifies the anti-PD-L1 antibody treatment as effective.
    Type: Application
    Filed: March 30, 2018
    Publication date: October 4, 2018
    Inventors: Brandon Higgs, Koustubh Ranade, Carlos Bais, Philip Brohawn, Michael Kuziora, Rajiv Raja
  • Compositions and Methods for Identifying B Cell Malignancies Responsive to B Cell Depleting Therapy
    Publication number: 20170088628
    Abstract: The invention provides compositions and methods featuring the use of miR-629 for identifying subjects responsive to B-cell depleting therapies (e.g., treatment with an anti-CD19 antibody). In other embodiments, the invention features the use of miR-629 to identify subjects as having a B cell malignancy.
    Type: Application
    Filed: December 9, 2016
    Publication date: March 30, 2017
    Inventors: Yihong Yao, Katie Streicher, Koustubh Ranade, Philip Z. Brohawn, Michael Kuziora
  • COMPOSITIONS AND METHODS FOR IDENTIFYING B CELL MALIGNANCIES RESPONSIVE TO B CELL DEPLETING THERAPY
    Publication number: 20150252431
    Abstract: The invention provides compositions and methods featuring the use of miR-629 for identifying subjects responsive to B-cell depleting therapies (e.g., treatment with an anti-CD19 antibody). In other embodiments, the invention features the use of miR-629 to identify subjects as having a B cell malignancy.
    Type: Application
    Filed: March 4, 2015
    Publication date: September 10, 2015
    Inventors: YIHONG YAO, KATIE STREICHER, KOUSTUBH RANADE, PHILIP Z. BROHAWN, MICHAEL KUZIORA
  • Methods of preparing amplified nucleic acid molecules
    Publication number: 20030129624
    Abstract: New and improved methods are provided for generating amplified nucleic acid molecules from cellular mRNA. The methods are robust and reliable, and can be used to provide gene fragments for use in methods of analyzing gene expression patterns.
    Type: Application
    Filed: September 17, 2002
    Publication date: July 10, 2003
    Applicant: GENE LOGIC, INC.
    Inventors: Eric Eastman, Glenn Hoke, John Hartwell, Larry Millstein, Michael Kuziora, Richard Guilfoyle